Paris, France, February, the 11th, 2004
Press Release
Cellectis announces a License agreement with Regeneron Pharmaceuticals relating to the use of the Homologous Recombination in Velocigene© Platform
Paris, France - February the 11th, 2004 - Cellectis, the rational genome engineering company, announced today they entered into a non-exclusive worldwide license agreement in which Cellectis has granted to Regeneron rights under its patent family relating to the use of homologous recombination for the specific replacement or insertion of a gene in the mouse genome.
Through this agreement, Regeneron will use this patented technology in its Velocigene© platform, which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized modification of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.
Velocigene© accelerates gene function discovery and validation of new drug targets through rapid and high-throughput creation of important in vivo model systems.
Financial terms and conditions of the agreement were not disclosed.
"We are extremly pleased about this important agreement with a leading biopharmaceutical company such as Regeneron Pharmaceuticals, Inc." said Isabelle Pelletier-Bressac, VP Business Development of Cellectis. "This new agreement confirms that these patents, covering certain uses of homologous recombination, play a critical role in this area" she added.
Cellectis SA (http://www.cellectis.com) was founded in 1999, as a spin-off from the Institut Pasteur. It is the first company to apply the Meganuclease Recombination System approach to in vivo genome engineering. The company is developing Meganucleases that can target a unique DNA break in vivo, as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery, agriculture and industrial biotechnology.
As of today, Cellectis has entered into more than 20 deals on Genome Engineering technologies.
Copyright © Cellectis 2004. All rights reserved.
|
